<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of topical recombinant interferon alfa 2c hydrogel (IFN alpha 2C) in the aphthous lesions of the mouth in <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's syndrome</z:e> was assessed in twenty patients in a twelve-week open trial </plain></SENT>
<SENT sid="1" pm="."><plain>IFN alpha 2C applied to the mouth for four weeks significantly reduced the number of <z:e sem="disease" ids="C0038363" disease_type="Disease or Syndrome" abbrv="">aphthae</z:e> in the post-treatment phase compared to the pretreatment and treatment phases </plain></SENT>
<SENT sid="2" pm="."><plain>No side effects were recorded </plain></SENT>
<SENT sid="3" pm="."><plain>Topical IFN alpha 2C seems to be effective in the treatment of the <z:e sem="disease" ids="C0038363" disease_type="Disease or Syndrome" abbrv="">aphthae</z:e> in <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's syndrome</z:e> </plain></SENT>
</text></document>